American Century Companies Inc. lifted its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,048 shares of the specialty pharmaceutical company’s stock after buying an additional 1,001 shares during the quarter. American Century Companies Inc. owned about 0.16% of Supernus Pharmaceuticals worth $2,692,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in SUPN. Meeder Asset Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 511.1% in the fourth quarter. Meeder Asset Management Inc. now owns 880 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 736 shares in the last quarter. Advisor Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 17.2% in the fourth quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 306 shares in the last quarter. Cutler Group LP bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $89,000. Laurion Capital Management LP bought a new position in shares of Supernus Pharmaceuticals in the third quarter valued at $207,000. Finally, Assenagon Asset Management S.A. bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $223,000. 99.18% of the stock is owned by institutional investors and hedge funds.
Several research firms recently weighed in on SUPN. BidaskClub raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 4th. Mizuho reissued a “buy” rating and issued a $63.00 target price on shares of Supernus Pharmaceuticals in a research note on Thursday, March 28th. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. ValuEngine cut shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Finally, B. Riley set a $65.00 target price on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, March 4th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $55.75.
SUPN stock opened at $37.72 on Tuesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.06 and a quick ratio of 2.90. Supernus Pharmaceuticals Inc has a one year low of $30.05 and a one year high of $61.25. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of 18.40 and a beta of 1.59.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.19. Supernus Pharmaceuticals had a net margin of 27.14% and a return on equity of 27.45%. The firm had revenue of $113.50 million during the quarter, compared to analysts’ expectations of $105.36 million. During the same period in the previous year, the business posted $0.26 earnings per share. The company’s revenue for the quarter was up 31.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Supernus Pharmaceuticals Inc will post 2.37 earnings per share for the current fiscal year.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Further Reading: How to Use the New Google Finance Tool
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.